I assume the most likely place for U. Penn to discuss the radiological biomarkers, associated with efficacy determination in the trial, will be at ASCO’s Industry expert theater. There’s a two day old article in Nature’s “Scientific Reports” about radiology determinations for GBM, written by U. Penn. It is extremely comprehensive. Dr. Mohan was one of the coauthors. He is also supposed to be the physician that will head the U. Penn team presentation on as yet unpublished radiology efficacy data (for the trial) in June.
Scientific Reports is a rigorously peer reviewed journal by Nature.
Market Data 
Markets 
AI
